Skip to main content
Fig. 6 | Cost Effectiveness and Resource Allocation

Fig. 6

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

Fig. 6

Cost-effectiveness acceptability curves showing the probabilities of net benefits achieved by each strategy for different willingness-to-pay thresholds (the maximum amount a person would be willing to pay for a good) in ACTH (a) and TCH(b) cohorts. The vertical axes represent the probability of cost-effectiveness. The horizontal axes represent willingness-to-pay thresholds to gain one additional quality-adjusted life year (QALY). For example, if the threshold was set at $20,000 per QALY, the probability of cost-effectiveness of TCH was highest

Back to article page
\